Other Announcements - 2023
Intimation of Schedule of Analyst / Institutional Investor Meetings November 2023
November 16, 2023
Glenmark Pharmaceuticals receives ANDA approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg
November 7, 2023
Glenmark Pharma is first to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-morbidities
October 18, 2023
Glenmark Pharmaceuticals receives ANDA approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg
October 17, 2023
Ichnos Sciences Enters Licensing Agreement For OX40 Antagonist Monoclonal Antibody Portfolio with Astria Therapeutics OCT 23
October 12, 2023
Notice of Postal Ballot – Disclosure under Regulation 30 of the SEBI LODR Regulations, 2015
October 6, 2023
Credit Rating- Glenmark Pharmaceuticals Outlook Revised to Positive on proposed GLS Stake Sale; ”BB” Rating Affirmed
September 28, 2023
Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa
September 27, 2023
Credit Rating-India Ratings has discontinued and withdrawn the outstanding voluntary issuer ratings disclosure due to regulatory requirements
September 23, 2023
Glenmark Pharma announces Proposed Divestment of Majority Stake in Glenmark Life Sciences
September 21, 2023
Press Release of our wholly owned subsidiary company relating to Antitrust settlement with DOJ
August 22, 2023
Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%
August 17, 2023
Glenmark Pharmaceuticals receives ANDA approval for Saxagliptin Tablets, 2.5 mg and 5 mg
August 1, 2023
Newspaper Advertisement – Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
July 6, 2023
Notice of Postal Ballot – Disclosure under Regulation 30 of the SEBI LODR Regulations, 2015
July 5, 2023
Exchange Notification: Glenmark becomes a part of the Science Based Targets initiative, sets GHG emissions targets for FY 2035
May 31, 2023